
Hazel Dockrell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8076479/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Diabetes is associated with genotypically drug-resistant tuberculosis. European Respiratory Journal, 2020, 55, 1901891.	6.7	13
2	Diagnostic Potential of a PPE Protein Derived from <i>Mycobacterium tuberculosis</i> Beijing/K Strain. Yonsei Medical Journal, 2020, 61, 789.	2.2	2
3	A Feasibility Study for Diagnosis of Latent Tuberculosis Infection Using an IGRA Point-of-Care Platform in South Korea. Yonsei Medical Journal, 2019, 60, 375.	2.2	8
4	Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment. Genes and Immunity, 2015, 16, 347-355.	4.1	35
5	Acquired immunodeficiencies and tuberculosis: focus on <scp>HIV</scp> / <scp>AIDS</scp> and diabetes mellitus. Immunological Reviews, 2015, 264, 121-137.	6.0	87
6	Investigating the non-specific effects of BCG vaccination on the innate immune system in Ugandan neonates: study protocol for a randomised controlled trial. Trials, 2015, 16, 149.	1.6	11
7	Genetic diversity of Mycobacterium tuberculosis isolated from tuberculosis patients in the Serengeti ecosystem in Tanzania. Tuberculosis, 2015, 95, 170-178.	1.9	24
8	The impact of maternal infection with <i>Mycobacterium tuberculosis</i> on the infant response to bacille Calmette–Guérin immunization. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140137.	4.0	23
9	Mycobacterial load affects adenosine deaminase 2 levels of tuberculous pleural effusion. Journal of Infection, 2015, 71, 488-491.	3.3	9
10	Impact of Co-Infections and BCG Immunisation on Immune Responses among Household Contacts of Tuberculosis Patients in a Ugandan Cohort. PLoS ONE, 2014, 9, e111517.	2.5	30
11	Screening vaccine formulations for biological activity using fresh human whole blood. Human Vaccines and Immunotherapeutics, 2014, 10, 1129-1135.	3.3	9
12	Identification of Immunological Biomarkers Which May Differentiate Latent Tuberculosis from Exposure to Environmental Nontuberculous Mycobacteria in Children. Vaccine Journal, 2014, 21, 133-142.	3.1	30
13	Differences in <scp>T</scp> â€cell responses between <i><scp>M</scp>ycobacterium tuberculosis</i> and <i><scp>M</scp>ycobacterium africanum</i> â€infected patients. European Journal of Immunology, 2014, 44, 1387-1398.	2.9	21
14	TANDEM: understanding diabetes and tuberculosis. Lancet Diabetes and Endocrinology,the, 2014, 2, 270-272.	11.4	48
15	Differential gene expression of activating FcÎ ³ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clinical Microbiology and Infection, 2014, 20, O230-O238.	6.0	65
16	Factors affecting immunogenicity of BCG in infants, a study in Malawi, The Gambia and the UK. BMC Infectious Diseases, 2014, 14, 184.	2.9	27
17	Circulating B-Lymphocytes as Potential Biomarkers of Tuberculosis Infection Activity. PLoS ONE, 2014, 9, e106796.	2.5	29
18	Inhibition of Mycobacterial Growth <i>In Vitro</i> following Primary but Not Secondary Vaccination with Mycobacterium bovis BCG. Vaccine Journal, 2013, 20, 1683-1689.	3.1	85

HAZEL DOCKRELL

#	Article	IF	CITATIONS
19	Detection of Tuberculosis in HIV-Infected and -Uninfected African Adults Using Whole Blood RNA Expression Signatures: A Case-Control Study. PLoS Medicine, 2013, 10, e1001538.	8.4	314
20	Distinct Phases of Blood Gene Expression Pattern Through Tuberculosis Treatment Reflect Modulation of the Humoral Immune Response. Journal of Infectious Diseases, 2013, 207, 18-29.	4.0	218
21	Analysis of Host Responses to Mycobacterium tuberculosis Antigens in a Multi-Site Study of Subjects with Different TB and HIV Infection States in Sub-Saharan Africa. PLoS ONE, 2013, 8, e74080.	2.5	48
22	Combination of Cytokine Responses Indicative of Latent TB and Active TB in Malawian Adults. PLoS ONE, 2013, 8, e79742.	2.5	39
23	A New Challenge for the Tuberculosis Vaccine Community?. Journal of Infectious Diseases, 2012, 205, 1029-1031.	4.0	1
24	Variability between countries in cytokine responses to BCG vaccination: what impact might this have on protection?. Expert Review of Vaccines, 2012, 11, 121-124.	4.4	9
25	New Biomarkers with Relevance to Leprosy Diagnosis Applicable in Areas Hyperendemic for Leprosy. Journal of Immunology, 2012, 188, 4782-4791.	0.8	73
26	Long-Lived Memory B-Cell Responses following BCG Vaccination. PLoS ONE, 2012, 7, e51381.	2.5	44
27	The Current Status of BCG Vaccination in Young Children in South Korea. Tuberculosis and Respiratory Diseases, 2012, 72, 374.	1.8	9
28	Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy. Memorias Do Instituto Oswaldo Cruz, 2012, 107, 79-89.	1.6	55
29	Broad heparinâ€binding haemagglutininâ€specific cytokine and chemokine response in infants following Mycobacterium bovis <scp>BCG</scp> vaccination. European Journal of Immunology, 2012, 42, 2511-2522.	2.9	17
30	Evaluation of cell-mediated immune responses to two BCG vaccination regimes in young children in South Korea. Vaccine, 2011, 29, 6564-6571.	3.8	8
31	BCG Vaccination: A Role for Vitamin D?. PLoS ONE, 2011, 6, e16709.	2.5	44
32	Analysis of Antibody Responses to <i>Mycobacterium leprae</i> Phenolic Glycolipid I, Lipoarabinomannan, and Recombinant Proteins To Define Disease Subtype-Specific Antigenic Profiles in Leprosy. Vaccine Journal, 2011, 18, 260-267.	3.1	65
33	Another Step Down the Development Pipeline for the Novel Tuberculosis Vaccine MVA-85A. Journal of Infectious Diseases, 2011, 203, 1708-1709.	4.0	0
34	BCG Vaccination Induces Different Cytokine Profiles Following Infant BCG Vaccination in the UK and Malawi. Journal of Infectious Diseases, 2011, 204, 1075-1085.	4.0	134
35	Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. BMC Immunology, 2010, 11, 35.	2.2	40
36	Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine, 2010, 28, 1635-1641.	3.8	71

HAZEL DOCKRELL

#	Article	IF	CITATIONS
37	Presidential address: the role of research networks in tackling major challenges in international health. International Health, 2010, 2, 181-185.	2.0	12
38	Identification of Major Factors Influencing ELISpot-Based Monitoring of Cellular Responses to Antigens from Mycobacterium tuberculosis. PLoS ONE, 2009, 4, e7972.	2.5	46
39	Population Differences in Immune Responses to Bacille Calmetteâ€Guérin Vaccination in Infancy. Journal of Infectious Diseases, 2009, 199, 795-800.	4.0	100
40	From Genome-Based In Silico Predictions to Ex Vivo Verification of Leprosy Diagnosis. Vaccine Journal, 2009, 16, 352-359.	3.1	45
41	A Courageous Step Down the Road toward a New Tuberculosis Vaccine. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 628-629.	5.6	4
42	Immunogenicity of Novel DosR Regulon-Encoded Candidate Antigens of <i>Mycobacterium tuberculosis</i> in Three High-Burden Populations in Africa. Vaccine Journal, 2009, 16, 1203-1212.	3.1	148
43	Building research capacity through international partnerships. International Health, 2009, 1, 109-110.	2.0	1
44	CCL2 Responses to Mycobacterium tuberculosis Are Associated with Disease Severity in Tuberculosis. PLoS ONE, 2009, 4, e8459.	2.5	64
45	Differences between naive and memory T cell phenotype in Malawian and UK adolescents: a role for Cytomegalovirus?. BMC Infectious Diseases, 2008, 8, 139.	2.9	47
46	Persistence of the immune response induced by BCG vaccination. BMC Infectious Diseases, 2008, 8, 9.	2.9	73
47	Biomarkers for TB treatment response: Challenges and future strategies. Journal of Infection, 2008, 57, 103-109.	3.3	57
48	Molecular methods for distinguishing between relapse and reinfection in leprosy. Tropical Medicine and International Health, 2008, 13, 1325-1326.	2.3	4
49	A comparison of IFNÎ ³ detection methods used in tuberculosis vaccine trials. Tuberculosis, 2008, 88, 631-640.	1.9	47
50	Real vaccines in the real world: tuberculosis vaccines move south. Expert Review of Vaccines, 2008, 7, 703-707.	4.4	5
51	Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations. PLoS Medicine, 2008, 5, e145.	8.4	82
52	Reply to Davies et al Journal of Infectious Diseases, 2007, 196, 649-650.	4.0	1
53	Utility of interferon-γ ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South Africa. BMC Infectious Diseases, 2007, 7, 99.	2.9	54
54	Leprosy vaccines. Vaccine, 1991, 9, 291-293.	3.8	4

Leprosy vaccines. Vaccine, 1991, 9, 291-293.

3.8 4